Sanofi Profits Continue To Recede

BMI View: Sanofi's share price will outperform BMI's Pharma 20 Index over the next three months. The company's Q211 results illustrate its high exposure to healthcare sector cost-containment programmes and the ongoing patent cliff, under which almost all leading blockbusters will lose patent protection, is also sure to continue to affect revenues. However, we believe the company's investment in creating a product portfolio of high-value drugs, in addition to its focus on creating a more streamlined business and its focus on industry-driven emerging markets, will enable it to post healthy financials.

To read the full article, please choose one of the following options: